BioGraphene Signs Collaboration Agreement with University of Notre Dame for BGN-112’s Pharmacodynamic Study
BioGraphene Inc. announced that the company and the Warren Family Research Center for Drug Discovery and Development at the University of Notre Dame entered into a Collaboration Agreement for BGN-112’s pharmacodynamic study.
This study will validate BGN-112’s pharmacodynamics across multiple subcellular targets in Niemann-Pick Disease Type C and other diseases. As a part of the study, it will assess BGN-112’s role in inducing effects in elevating the level of heat shock proteins for chaperone-mediated therapeutic outcomes and as standalone synthetic chaperones.
The Warren Family Research Center for Drug Discovery and Development (Warren Center) at the University of Notre Dame is a state-of-the-art resource for a highly productive and renowned group of drug discovery faculty with expertise and interest in areas such as neurological and central nervous system disorders, infectious disease, cancer and rare diseases. The Warren Center supports the organization of chemical research discoveries for the Notre Dame Chemical Compound Collection and promotes biological evaluation of the products through internal collaborations and external partnerships with the aim of bringing healing therapies to market.